Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $30.25 Consensus PT from Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been assigned an average rating of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $30.25.

Several analysts have issued reports on BCAX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Citizens Jmp initiated coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They set a “market perform” rating and a $31.00 target price on the stock. Mizuho upgraded Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. HC Wainwright reissued a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Finally, Citigroup started coverage on Bicara Therapeutics in a report on Thursday, January 29th. They set an “outperform” rating for the company.

Bicara Therapeutics Trading Down 0.1%

Bicara Therapeutics stock opened at $18.39 on Friday. Bicara Therapeutics has a 12-month low of $7.80 and a 12-month high of $20.25. The firm has a 50-day moving average price of $17.00 and a 200-day moving average price of $16.38. The firm has a market capitalization of $1.01 billion, a PE ratio of -8.21 and a beta of -0.78.

Insiders Place Their Bets

In related news, CEO Claire Mazumdar sold 1,596 shares of Bicara Therapeutics stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $18.95, for a total transaction of $30,244.20. Following the completion of the sale, the chief executive officer owned 339,392 shares in the company, valued at $6,431,478.40. This trade represents a 0.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Ivan Hyep sold 2,963 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $18.25, for a total transaction of $54,074.75. Following the completion of the sale, the chief financial officer directly owned 145,355 shares of the company’s stock, valued at approximately $2,652,728.75. This trade represents a 2.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 128,769 shares of company stock valued at $2,415,814 in the last three months.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Legal & General Group Plc increased its holdings in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after buying an additional 1,474 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after buying an additional 3,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Bicara Therapeutics during the 4th quarter worth $45,000. Finally, Larson Financial Group LLC increased its stake in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after buying an additional 3,595 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.